Controlled rot, responsible for most of what people like.
Pfizer’s origin story is not about curing disease — it is about solving chemical supply problems with fermentation. Its therapeutic dominance came decades after it mastered industrial microbiology under pressure.
Boehringer Ingelheim is a rare case of sustained private ownership enabling both technical continuity (from lactic acid to biopharma) and social infrastructure (welfare policies pre-dating national systems). Its business model is not about disruption but compound discipline: owning the science, the scale, and the staff.
Danone’s origin is a tightly documented sequence: a Barcelona workshop, a legal name fix, physician validation, pharmacy distribution, then expansion. No funding rounds, no founder mythmaking — just regulatory adaptation and clinical credibility turned into commerce.
Meituan is a Chinese technology company headquartered in Beijing that operates a platform for local services, including on‑demand food delivery, in‑store services, consumer reviews under Dazhong Dianping, hotel and travel bookings, and instant retail. It monetises through fees on its platform, taking a commission on food delivery orders and charging merchants for booking and in‑store services. Meituan’s rapid user growth is driven by its extensive coverage of local services, its integration of food delivery, in‑store services, and hotel bookings creating a one‑stop shop, and its large merchant base of 14.5 million active merchants providing network effects. Meituan faces regulatory scrutiny in China, its 2021 post by Wang Xing triggered a 7.1 % share plunge and anti‑monopoly investigation, and the company has been subject to scrutiny by Beijing Municipal Human Resources and Social Security Bureau. Meituan demonstrates the power of a diversified local‑services platform, its ability to scale across cities and internationally shows the importance of network effects, and its regulatory challenges highlight the need for compliance awareness. Meituan offers a case study in rapid scaling and diversification, but its regulatory risks caution investors.
ABB is a post-merger industrial incumbent whose value lies in proven, regulated, physical infrastructure — not software, platforms, or scalability stories.